Drinkable yogurt containing Lactobacillus paragasseri SBT2055,
does it really help with Fewer questionnaire-recorded days with common-cold-like symptoms during winter?
research showsGrade C. The primary endpoint in this 200-person randomized trial was days with questionnaire-recorded cold-like symptoms. Runny nose occurred on 2,384/8,148 days (29.3%) versus 2,769/8,066 days (34.3%), an absolute difference of -5.0 points, P<.001. This means fewer symptom-days, not fewer laboratory-confirmed colds.
ads claimBecause the control was identical yogurt without LG2055, the trial asks about the added strain's effect on symptom-days. It does not establish fewer infections, laboratory-confirmed cold prevention, or a general immune boost.
Useful facts when choosing a product
- The active and control yogurts differed by LG2055.
- The paper did not report between-group 95% confidence intervals.
- Exactly 200 participants were randomized, so this was not below the 200-person threshold.
What the research actually shows
The Japanese trial randomized 200 healthy adults aged 20-64 who were prone to colds, 100 per group, to 12 weeks of LG2055 yogurt or identical yogurt lacking only LG2055. Of 198 completers, five were excluded, leaving a 193-person per-protocol efficacy set (97/96). EK, TA, MK, and TK were employees of MEGMILK SNOW BRAND, and NS worked for contract research organization KSO Corporation. The product was the company's LG2055 drinkable yogurt; no separate public cofunding, medical-writing, or publication support was identified. Although the paper said registration preceded initiation, the UMIN public date of September 8, 2022 followed the planned October 30, 2021 start, making it retrospectively public by the registry record.
Why this is classified as C (50)
One manufacturer-program trial with a 193-person per-protocol primary efficacy analysis gives C with 50 points.
Counterpoint. Symptom-days decreased, but that is distinct from reducing cold infections.
Rejudgment record. Cross-check applied — Single manufacturer-linked RCT, retrospectively public registration, 193-person per-protocol efficacy analysis, and questionnaire symptom-day endpoint
| Endpoint | P | Patient-reported treatment goal - the symptom is the goal |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
The scoring table and the verdict agree (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Fewer questionnaire-recorded cold-like symptom-days | C | Several symptom-day proportions were lower, but 95% CIs were not reported. |
| Fewer cold infections | ? | The trial did not measure laboratory-confirmed infection incidence. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Double-blind randomized identical-yogurt placebo-controlled parallel trial | 96 | Four MEGMILK SNOW BRAND employee authors and a company-developed product | Days with questionnaire-recorded cold-like symptoms over 12 weeks | Runny nose 29.3% vs 34.3%, absolute difference -5.0 points, P<.001; no 95% CI reported | Primary questionnaire symptom-day endpoint |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-26).
Final verification and publication gate: Codex · Verification cutoff: 2026-08-26 · Corrections: none
Cite this verdict
[Chamgap] Benefit of LG2055 Drinkable Yogurt for Days With Common-Cold-Like Symptoms — Evidence Grade C·50. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/lg2055-drinking-yogurt-common-cold-symptom-days/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.